Cushing's disease is the most common form of endogenous Cushing's syndrome and results from excess adrenocorticotropic hormone (ACTH) production by a corticotroph pituitary adenoma. Transsphenoidal surgical removal of the corticotroph adenoma is the treatment of choice for patients with Cushing's disease. However, despite advances in surgery, complete tumour removal is sometimes impossible and eventual disease recurrence occurs later even in patients who achieved an initial remission. Medical therapy is one of the second-line options, which can provide a primary or adjunctive role if the patient cannot safely undergo pituitary surgery, if surgery fails, or if the tumour recurs. However, until recently, few effective therapeutic options existed. Somatostatin receptors in the corticotroph tumours have been identified as potential therapeutic targets for Cushing's disease. Pasireotide is a novel somatostatin analogue which has high affinity for these receptors. In a recent Phase III clinical trial, pasireotide treatment was demonstrated to significantly reduce elevated cortisol levels in patients with Cushing's disease achieving normalisation of urinary free cortisol (UFC) levels in subset of patients and close to 50 % mean reduction in UFC levels were seen in the patients. Initial data also suggest that pasireotide could be highly effective as part of combined therapy for Cushing's disease.
overall lower rate of success than that seen after the first operation. 11 These findings suggest a need for new therapies to treat patients with Cushing's disease who fail to achieve remission following surgical intervention.
Second-line Therapy When Pituitary Surgery Fails
Unlike other hormone secreting pituitary tumours, medical therapy is generally not considered as a first-line treatment option for patients with Cushing's disease. 8 The role of medical therapy has until recently only been administered short-term or while awaiting effectiveness of other therapeutic approaches: it is sometimes performed before surgery to minimise complications and to reduce the effects of severe hypercortisolism. In patients for whom surgery has failed, medical therapy is necessary to reduce elevated levels of cortisol and should be attempted before considering bilateral adrenalectomy. Medical therapy can also be useful in patients waiting for pituitary radiotherapy to take effect, which can take up to 2-3 years or more. 8, 12 Effective medical treatment of Cushing's disease that targets directly the corticotroph tumour therefore represents an unmet clinical need.
Medical Therapies Targeted to Adrenal Glands and Glucocorticoids Receptors
Adrenal-directed therapy using the steroidogenesis inhibitors ketoconazole, metyrapone, mitotane and etomidate have been effective as palliative treatment in a significant proportion of patients; however, they all target the adrenal glands and do not treat the underlying cause of the disease. 8 Each of the medical therapies utilised in the treatment of Cushing's disease have their specific drawbacks and are not equally accessible in all countries (see Table 2 ). Monitoring of systemic levels of liver enzymes is needed during ketoconazole treatment because of the potential of hepatotoxicity; 13 in addition ketoconazole suppresses testosterone levels and is thus not the first choice in male patients with Cushing's disease. Metyrapone inhibits 11-hydroxylase to decrease cortisol levels producing an increase of ACTH levels and accumulation of precursor steroids including adrenal androgens and mineralocorticoid precursors; this can result in hypertension, hypokalaemia and hirsutism in women. 1 LCI699 is a new potent inhibitor of 11-beta-hydroxylase, the enzyme responsible for the last step of cortisol synthesis. The safety and efficacy of this drug are currently being evaluated, 14 however preliminary data has demonstrated efficacy with a satisfactory safety profile in a short-term proof-of-concept study. 15 Mitotane has been used in few centres probably in view of dose-related gastrointestinal and neurological adverse effects (AEs). 16 
Medical Therapies Targeting the Corticotroph Tumours
Recent advances in understanding of the pathogenesis of corticotroph tumours have led to the investigation of pituitary tumour-directed drugs in the treatment of Cushing's disease. Cabergoline is a D2 dopamine receptor agonist that is approved by the US Food and Drug Administration (FDA) as a therapy for hyperprolactinaemia. 19 As dopamine receptors are expressed in a subset of pituitary corticotroph tumours of patients with Cushing's disease, cabergoline has been evaluated as a potential therapy. 20 It has been found that cabergoline is able to normalise urinary free cortisol in 25-40 % of patients with Cushing's disease over 2-5 year follow-up, but the studies are limited to few single-centre prospective studies [21] [22] [23] and a retrospective study from two centres, 24 where each study included only 12-30 patients.
Furthermore, the doses used varied between 1 to 7 mg/week, raising the need to monitor for long-tem potential cardiac valvulopathy and eventual escape phenomenon. 22 A recent pilot study using retinoic acid (up to 80 mg daily orally) shows some potential efficacy over 12 months but was effective in only three of seven patients during one year. 25 The somatostatin analogue pasireotide is the first drug to be approved 30 The primary target patient population was those with persistent or recurrent Cushing's disease and treatment naive patients could only be enrolled the lower bound of the 95 % CI for a dose group was greater than 15 %), however, the 600 μg treatment arm failed to meet this criterion.
There was a rapid decrease in UFC, with a median 50 % reduction in UFC level in both dosage groups by month two and this remained stable up to month 12. In the majority of patients evaluable at month six, a decrease in UFC was seen from baseline to month six and almost half (48.5 %) achieved a substantial reduction (≥ 50 %) in UFC (see Figure 1) . In general, patients allocated to receive 900 μg of pasireotide had lower UFC levels than those randomised to the 600 μg dose. It is important to note that the population of patients enrolled in this study was composed of patients with moderate to severe hypercortisolism (78 % of patients) with mean baseline UFC of 6.5 times ULN. Higher baseline UFC are associated with a lower normalisation rate of UFC. In patients with mild hypercortisolism at baseline (UFC 1.5 to 2 x ULN), the efficacy was as high as 50 % in the 900 μg bid group (see Figure 2) . 30 The biochemical response in UFC was also supported by reductions in serum cortisol, plasma ACTH and pituitary tumour size.
Significant improvements in the signs and symptoms of Cushing's disease were also seen, including reductions in body weight, reductions in systolic and diastolic blood pressure and decreases in low-density lipoprotein (LDL) cholesterol levels (see Figure 3) .
Scores for health-related quality of life also improved. These improvements were seen regardless of whether a normal UFC was In the B2305 trial, patients unlikely to have a biochemical response to pasireotide treatment could be identified within the first few months of treatment; of the patients who were uncontrolled at both month one and two, (who did not have at least a 50 % reduction in UFC from baseline and their UFC was above ULN), 91.7 % were uncontrolled at month six. 30 Analyses of the prediction value of early response to pasireotide have shown that in general most patients who have an early response to pasireotide continue to respond, while the majority of patients who fail to respond biochemically to pasireotide within the first two months do not respond at a later time point. 35 The patient factors involved in Colao et al., 2012. 30 responsiveness to pasireotide are currently unknown, however future studies on correlations between levels of expression of sst 5 in corticotroph tumours and response to pasireotide may aid in appropriate treatment decisions.
Since human corticotroph adenomas express both sst and dopamine receptors, combined therapy involving somatostatin analogues and dopamine agonists (pasireotide + cabergoline) may be a promising approach for patients who fail to achieve normal UFC levels when given cabergoline or pasireotide alone. In a recent study 17 patients with Cushing's disease were treated with 100 μg of pasireotide three times daily; this dose was increased to 250 μg subcutaneously three times daily at day 15 if the level of UFC had not normalised.
At day 28, cabergoline was added to pasireotide at a dose of 0. The addition of cabergoline normalised UFC in a further 24 %.
At day 60, a total of 47 % still had elevated UFC levels with pasireotide-cabergoline combination therapy, although a trend toward normalisation of UFC was observed in all but one patient. Medical Treatment of Cushing's Disease with Pasireotide 
Summary and Concluding Remarks
Cushing's disease is a serious endocrine disease for which currently surgery remains the first-line treatment, but unfortunately the rate of remission at long-term follow-up is suboptimal and recurrences are 
